Evercore ISI lowered the firm’s price target on Bio-Techne (TECH) to $54 from $68 and keeps an In Line rating on the shares as part of the firm’s medical technology and life science tools Q1 preview.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH: